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Background: Chronic Fatigue Syndrome (CFS) is a debilitating neuro-immune disorder of unknown etiology
diagnosed by an array of clinical manifestations. Although several immunological abnormalities have been
described in CFS, their heterogeneity has limited diagnostic applicability.
Methods: Immunological features of CFS were screened in 22 CFS diagnosed individuals fulfilling Fukuda criteria
and 30 control healthy individuals. Peripheral blood T, B and NK cell function and phenotype were analyzed by
flow cytometry in both groups.
Results: CFS diagnosed individuals showed similar absolute numbers of T, B and NK cells, with minor differences in
the percentage of CD4+ and CD8+ T cells. B cells showed similar subset frequencies and proliferative responses
between groups. Conversely, significant differences were observed in T cell subsets. CFS individuals showed
increased levels of T regulatory cells (CD25+/FOXP3+) CD4 T cells, and lower proliferative responses in vitro and
in vivo. Moreover, CD8 T cells from the CFS group showed significantly lower activation and frequency of effector
memory cells. No clear signs of T-cell immunosenescence were observed. NK cells from CFS individuals displayed
higher expression of NKp46 and CD69 but lower expression of CD25 in all NK subsets defined. Overall, T cell and
NK cell features clearly clustered CFS individuals.
Conclusions: Our findings suggest that alterations in T-cell phenotype and proliferative response along with the
specific signature of NK cell phenotype may be useful to identify CFS individuals. The striking down modulation of
T cell mediated immunity may help to understand intercurrent viral infections in CFS.
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reproduction in any medium, provided the oractivity [1]. Classical diagnostic criteria for CFS overlap
with Myalgic Encephalomyelitis (ME) and require these
symptoms to be present for at least six months and
concomitant to at least four accompanying symptoms,
among them: impaired memory, adenopathy, myalgia or
polyartralgia [2]. The World Health Organization ac-
knowledged ME/CFS as a disease of the nervous system
(ICD G93.3) [3]. However, CFS is a multi-system disease,
in which neurological disorders are accompanied by al-
tered immune, musculoskeletal, endocrine and cardio-
vascular systems [4,5]. Research efforts have recently
provided a new International Consensus Criteria for ME
[3]. However, the search for the etiology(ies) and thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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wed several viral hypotheses including herpesviruses or
retroviruses as potential triggers of the disease [6-8]. The
potential role of pathogens in the CFS field has boosted
research in the immunological sides of the illness [9-11].
Indeed, the link between the immune system and CFS has
been explored since the early 90’s [12], and is supported
by the coincidence of the onset of symptoms with viral in-
fections [13], the persistence of several infections in CFS
individuals [10,14-17], the beneficial effect of treatment of
human herpesvirus 6 and Epstein-Bar virus infection in
CFS symptoms [18] and the reported role of autoimmun-
ity [19,20] Moreover, other features of ME/CFS, such as
mild inflammation, oxidative/nitrosative stress, mitochon-
drial dysfunction and the presence of autoimmunne re-
sponses [4] may alter immune function and phenotype.
However, the characterization of the immune status of
CFS individuals has frequently yield contradictory results.
Early work associated CFS with a general status of im-
mune activation assessed by CD38 or HLA-DR expression
in CD8 T cells [12]. However, other authors found similar
expression of these markers in CFS and healthy individ-
uals [21], while lower expression of the activation markers
CD69 or soluble CD26 has also been described as a fea-
ture of CFS [22,23]. Similarly, B-cell function [24], B-cell
mediated autoimmunity or unbalanced cytokine network
have been linked to CFS [9,25-27] again with inconclusive
results. Altered numbers of NK subsets, defined by CD56
or CD16 expression, and an impaired NK-cell lytic acti-
vity have been more consistently associated with CFS
[24,28-32], although controversial data have been also
reported [33] and a consensus in relevant NK cell markers
is still lacking.
At least some of these immune features described in
CFS may be related to active, poorly controlled viral in-
fections, which differently modulate immune responses
and may produce immune hyperactivation/exhaustion,
as widely reported for HIV [34]; may contribute to im-
munosenescence, as postulated for CMV [35]; or may
cause a status of immune anergy, as described for mea-
sles virus [36]. In this context, we sought to compare the
phenotype and function of different immune cells be-
tween healthy and ME/CFS individuals. The study was
designed in 2010 and could not include new definitions
that currently allow for the separation of ME and CFS
affected individuals [3]. However, our data point to an
unaffected B-cell compartment, a biased NK-cell pheno-
type and a poorly responsive T-cell compartment as the
main immune features of ME/CFS affected individuals.
Methods
Patients
A study to screen immunological features of patients
suffering from CFS was designed and approved by theEthics Committee of the Hospital Universitari Germans
Trias i Pujol (Barcelona, Spain; EO-10-007). All proce-
dures followed the Helsinki Declaration in 1975. The
main objective was to compare phenotypic and func-
tional alterations in immune cells between CFS patients
and healthy donors. Therefore, a wide range of pheno-
typic features was analyzed in a limited number of CFS
patients (N = 22) and controls (N = 30). CFS patients ful-
filled the Fukuda criteria [1]. Individuals were selected
from cohorts of CFS Clinical Units (CFS Unit, Tarra-
gona, Spain and Vall d’Hebron University Hospital, Bar-
celona, Spain). General exclusion criteria from these
cohorts were diabetes, hypertension, chronic obstructive
pulmonary disease, inflammatory bowel or Crohn's di-
sease, rheumatoid arthritis, Parkinson or Huntington
disorders, schizophrenia, organic mental disorders, sub-
stance use disorders, multiple sclerosis and body mnass
index BMI > 30 kg/m2. Eligible subjects were those with
age over 18 years, confirmed diagnosis of CFS for more
than two years and absence of current identified infec-
tions. Additional exclusion criteria were pregnancy and
chemotherapy treatment. In order to mirror the poten-
tial heterogeneity of CFS-affected, other major comor-
bidities associated to CFS were evaluated but were not
considered exclusion criteria. In particular, anxiety that
is an common feature of CFS affected individuals was
evaluated using HADS (Hospital Anxiety and Depres-
sion Scale) [37]. The severity of CFS was assessed using
a national scale [38]. Informed consent was obtained
from all participants in the study. Clinical and demo-
graphic data were collected from medical records.
Sample processing
A single blood sample was collected by venipuncture in
EDTA vacutainer tubes (BD Biosciences) from all partic-
ipants. An aliquot was used for immediate immunophe-
notype; remaining blood was processed for plasma and
peripheral blood mononuclear cells (PBMC) prepara-
tion by standard methods as described [39]. PBMC were
washed twice in PBS and resuspended in RPMI culture
medium for immediate analysis of proliferation, NK cell
activity or cell death assays. All samples were collected
and freshly processed at the Hospital Germans Trias i
Pujol. All samples were processed for immunophenotype
and function on the same day of blood collection, no
more than four hours were left between sample collec-
tion and immunophenotype staining, while no more
than six hours were left for functional and cell death
assays.
Determination of absolute counts of B, T and NK cells
Absolute counts of B, T and NK cells were analyzed by
flow cytometry. First, the absolute lymphocyte count
was determined using an anti-CD45–V450 antibody
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microspheres (Cytognos). Then, the percentage of the
different lymphocyte subsets was determined using the
following antibody combination: CD45–V450, CD19–
AmCyan, CD3–APC-Cy7, CD4–APC, CD8–PerCP, CD56–
PE and CD16–FITC (BD Biosciences). Absolute count
of each cellular population was calculated as follows:
(X*Y)/100, where X is the percentage of each subset
and Y is the absolute count of lymphocytes.
Immunophenotype
Freshly obtained blood was incubated for 15 minutes
at room temperature with the antibody combinations
shown in Table 1 in order to characterize B, T and NK
cell populations. All antibodies were from BD Bioscien-
ces unless indicated. Cells were then lysed for 15 minutes
at room temperature in FACS Lysing solution (BD Bio-
sciences), washed in PBS and fixed in PBS containing 1%
formaldehyde (Sigma), before acquisition in an LSRII
flow cytometer (BD Biosciences). For Ki67 and FOXp3
staining, two aliquots of fresh blood were incubated with
extracellular antibodies (Table 1) as indicated above. After
lysis, cells were washed and fixed/permeabilized using









T cells Thymic output/Exhaustion T1
T2
T3
CD8 activation T4 CD4
T5 CD4
Main subsets/senescence T6 CD45RA CD8
T7 CD8
Treg/Prolif./Anergy T8 CD4 CD8
T9 CD4 CD8
NK cells Activation/receptor profile NK1 CD69 CD3b/CD1
NK2 NKp46a,ed CD3b/CD1
NK3 CD3b/CD1





a Pacific blue-coupled antibody.
b AmCyan-coupled antibody.
c Alexa Fluor 647-coupled antibody.
d PerCP-Cy5.5 coupled antibody.
e sources different from BD Biosciences (NKp46 and CD57 from BioLegend; NKG2A
and CD10 from eBiosciences; IgG and IgA from Jackson ImmunoResearch, CD57 frowith anti Ki67 and FOXP3 antibodies or IgG isotype con-
trol antibodies (Table 1). Treg were defined by the pres-
ence of a separate population of CD25bright FOXP3+ cells.
B-cell and T-cell proliferation assays
Freshly obtained PBMC were stained with 0.33 μM
CFSE (Invitrogen) for 5 minutes at room temperature.
After extensive washes, cells were cultured in RPMI1640
medium supplemented with 10% of FBS (R10 medium)
and different stimulus. The proliferation of T cells was
assayed using 5 μg/mL of PHA (Sigma-Aldrich) plus
10 U/mL of IL-2 (Roche). For B cells, 3 μg/mL of en-
dotoxin-free CpG2006 (InvivoGen) or 1 μg/mL of R848
(Alexis Biochemicals) were used alone or in combination
with 5 μg/mL of F(ab)2 Goat anti-human Igs (Jackson
Immunoresearch). Four days later, cellular proliferation
was assessed by flow cytometry after staining T cells with
anti CD2–PerCP-Cy5.5, CD5–APC, CD4–V450, CD8–
APC-Cy7 and CD19–PE-Cy7 or B cells with CD3–APC-
Cy7, CD19–PE-Cy7, CD14–PerCP (BD Biosciences) and
IgD-APC (Miltenyi Biotec). Data analysis was performed
with the Flowjo software (Tree Star, Inc.), calculating div-
ision and proliferation indexes for each condition using







CD95 PD-1 CD4 HLA-DR CD8 CD3
CD45RA CD31 CD4 CD38d CD8 CD3
CD4 CD8 CD3
HLA-DR CD45RO CD38d CD8 CD3
CD8 CD3
CD57e CD28 CD27 CD4 CCR7 CD3
CD4 CD3
KI67 FOXP3e CD127c CD5d CD25 CD3
IRR IgG IRR IGG2ae CD3
9b CD107a Nkp44 CD57e CD25 CD56 CD16
9b CD107a NKG2De Nkp30 c NKG2Ae CD56 CD16
9b CD56 CD16
CD1c IgDe IgM CD38 CD27e CD19
CD23 IgDe CD5 CD38 CD10e CD19
IgDe CD19
CD1ce IgGe IgA CD38 CD27e CD19
IgGe IgAe CD19
from R&D Systems, NKG2D and CD1c from Santa Cruz; FOXP3, IRR IGG2a, CD27
m Beckman Coulter).
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Cell death was evaluated by culturing PBMC in of R10
medium at a density of 1 × 106 PBMC/ml for 24 hours
[34,40]. For T-cell death analysis, PBMC were incubated
with 40 nM of the potentiometric mitochondrial probe
DIOC6 (Invitrogen), 5 μg/mL propidium iodide (Sigma),
and CD3–APC-Cy7, CD4–APC and CD8–PE-Cy7 anti-
bodies. For B cell death analysis, PBMC were incubated
with 40 nM of DIOC6, 0.3 μM of Sytox Blue (Invitrogen)
and CD19–APC-Cy7, IgD–PE, CD38–PerCP-Cy5.5, CD5–
APC (BD Biosciences) and CD27–PE-Cy7 (eBiosciences).
Cells were acquired in an LSRII flow cytometer; dead cells
were identified by their low DIOC6 staining [41].
NK activity assays
Lytic activity of NK cells was assessed as described [42]
with slight modifications. Available samples of PBMC
(n = 16) were extensively washed to remove any trace of
EDTA from extraction tubes and monocytes/macro-
phages were removed by plastic adherence for 1 h at
37°C (5% CO2), this treatment removed 82.4% of mono-
cytes from PBMC samples (n = 13). Exponentially grow-
ing eGFP-K562 cells å(obtained through the AIDS
Research and Reference Reagent Program, from Dr.
Kantakamalakul [43]) were used as target cells. Incuba-
tions were performed in duplicate in 96 well plates by
seeding a fixed amount (10,000 target cells) alone or
with increasing amounts of monocyte-depleted PBMC in
R10 medium, covering a range from 80:1 to 2.5:1 ef-
fector:target cell ratios. Samples were incubated for 4 h
at 37°C (5% CO2) stained for 10 min with 5 μg/mL
Propidium Iodide (PI, Sigma) and acquired in a LSRII
flow cytometer. The percentage of dead (PI+) eGFP-
K652 cells in the gate of eGFP-K562 cells was calculated.
Clustering and statistical analyses
Continuous variables were expressed as the median (inter-
quartile range) and compared using the Mann–Whitney
non-parametric test. Discrete variables were described as
percentages (number of patients) and the chi-square or
Fisher exact test was used as appropriate. P values <0.05
were considered significant. Clustering of CFS and healthy
individuals was performed using the Cluster 3.0 software.Table 2 Main characteristics of individuals recruited in the stu
SFC
(N = 22)
Age (years, Median, IQR) 44 [40–50]
Gender (% of female) 73
Time from diagnosis (Years, Median, IQR) 3 [3–5]
Grade of Fatigue (Median, IQR) 3 [2–3]
Reported onset with viral infection (%) 53Data were normalized according to medians and clustered
using non-parametric correlations. Treeview 1.1 software
was used to generate and visualize dendrograms.
Results
Patient characteristics
The main characteristics of the individuals recruited for
the study are summarized in Table 2. Both Control and
CFS groups showed similar median age values (38 and
44 years, respectively, p = ns, Mann–Whitney test) and
were mostly composed by females (55% and 73% re-
spectively, p = ns, Fisher exact test). Patients suffering
from CFS showed a median [IQR] time from certified
diagnosis of 3 [3-5] years, with 53% of them reporting
onset of symptoms with viral infections. The median
grade of CFS assessed by a national scale [38] was 3,
while only three recruited individuals showed grade 2.
Grade 3 was comparable to mild level of severity (an ap-
proximate 50% reduction in pre-illness activity level)
according to the newest consensus criteria for ME [3].
Grade 2 is assignable to a moderate severity. No severe
cases were included in the study. Three individuals in
the CFS group were excluded from the analysis, one due
to a B cell lymphocytosis (B cells represented 24% of lym-
phocytes showing a total B cell count of 435 cells/μL, with
more than 85% of cells showing a IgD+IgM–CD23+CD27+
CD5+CD38– phenotype), one due to an IgA deficiency
and a third due to sample unavailability.
Additional factors that may modulate immune func-
tion such as comorbidities and polypharmacy associated
with CFS were also evaluated. Polypharmacy is described
in Table 3. The main potential interference of pharmacy
was homeopathy (52% of patients), antioxidants (52%)
and analgesics (42%, mainly paracetamol), which were
separately distributed among participants.. Regarding co-
morbidities, anxiety was the most prevalent; myalgia or
tendinopathy along with reported multiple chemical sen-
sitivity were also relevant (Additional file 1: Table S1).
Quantification of main lymphocyte subsets
The absolute numbers and percentages of B cells (CD19+),
NK cells (CD3-CD56+CD16+), T cells (CD3+), CD4 T cells
(CD3+CD4+) and CD8 T cells (CD3+CD8+) in the CD45+dy
HD P-value






Table 3 Self-reported polypharmacy in CFS affected individuals
Analgesics Antidepressants Anxiolytics Benzodiazepines Homeopa
Thy
Antioxidants
Patient # Paracetamol Ibuprofen Tramadol Duloxetine Pregabalin Diazepam
CFS1 - - - - - -
CFS2 - - - - - - + +
CFS3 - - - + - - + +
CFS4 - - - - - + + +
CFS5 - - - - - - + +
CFS6 - - - - - - + +
CFS7 - - - - - - + +
CFS8 - - - - - - + +
CFS9 - - - - - - + +
CFS10 - - - - - + + +
CFS11 - - - - - - - +
CFS12 + - + - + - - -
CFS13 - - - - - - - -
CFS14 + - - - - - - -
CFS15 + + - + + - - -
CFS16 + + - + + - - -
CFS17 + - - - - + - -
CFS18 + + - + + + - -
CFS19 - - - - - - - -
Daily antioxidant doses were: 500 mg omega-3 fatty acids (Docosahexaenoic acid DHA/Eicosapentaenoic acid EPA), 150 mg Methylsulfonylmethane, 150 mg alpha
lipoic àcid, 75 mg Superoxide dismutase (SOD), 50 mg N-Acetyl cisteine (NAC), 3,5 mg Zn2+ and 0.5 mg Cu2 + .
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and healthy donors (data not shown and Figure 1). How-
ever, significantly lower frequency of CD3+CD56+ lym-
phocytes was observed in the CFS group. Moreover, a
slightly unbalanced composition of the CD3+ cell sub-
set was also observed, showing a higher CD4 T-cell repre-
sentation in the CFS group (Figure 1).B-cell phenotype and function
The potential role of B cells on CFS has been reinforced
by recent data on the clinical benefit of Rituximab treat-
ment [19,20]. Thus, we characterized circulating B cells
using the antibody panels shown in Table 1. No signifi-
cant differences between groups were observed in the
percentage of IgD+, IgG+, IgA+ or CD27+ B cells, indi-
cating a similar memory compartment in CFS and con-
trol individuals. Moreover, the levels of transitional
(CD19+IgD+CD38highCD10+CD5+), plasma-plasmablas-
tic (CD19+CD27highCD38high) or marginal zone B cells
(CD19+IgD+IgM+CD27+CD1c+), were comparable in both
groups (Additional file 1: Figure S1). Consistently, func-
tional assessment of B-cell responses showed similar
proliferation to different stimuli targeting TLR9 and
TLR7/8, and similar level of ex vivo cell death (Additional
file 1: Figure S1 and data not shown). Thus, no majorperturbations on the phenotype and function of circula-
ting B cells could be identified.
NK-cell phenotype and function
NK-cell alterations have been classically associated with
CFS, showing decreased numbers and function [9,44].
Therefore, we evaluated the phenotype of NK cells using
the antibody panel shown in Table 1. The three main
NK-cell subsets identified in our gating strategy CD56high
CD16–, CD56+CD16+ and CD16+CD56– cells (Figure 2A)
and most of the markers analyzed were comparable bet-
ween groups (data not shown). However, the expression of
CD69 and NKp46 was significantly higher in CFS individ-
uals, while the expression of CD25, was significantly lower
(Figure 2B).
A phenotypic feature of NK cells from CFS individuals
is the low expression of CD57 [45]. Figure 2C shows that
in our study, the percentage of CD57 expressing NK
cells is similar among groups, although the intensity of
CD57 staining showed significantly lower values in CFS
individuals. Despite alterations in phenotype, NK cell cy-
totoxic activity did not reach significant differences bet-
ween groups in a subset of samples (9 CFS and 7 HD)
available for functional assays. Furthermore, no diffe-
rences in sensitivity of NK cells to ex vivo cell death








































































































































Figure 1 Analysis of major lymphocyte subsets in CFS affected individuals. Fresh blood was stained with anti CD45, CD19, CD3, CD4, CD8,
CD16 and CD56 antibodies. The percentage of NK (CD3–CD56+), B (CD19+) and T cells (CD3+) was analyzed in gated CD45+ lymphocytes.
Similarly, after gating CD3+ lymphocytes the percentage of CD4+, CD8+ or CD56+ cells was analyzed. Figures show data from healthy donors
(n = 24, HD) and SFC affected individuals (n = 17, SFC) with median values (lines), interquartile ranges (boxes) and 10–90 percentile values (bars).
In all cases, p-values for nonparametric Mann–Whitney comparison are shown.
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Several authors have pointed to a general status of T-cell
activation in CFS [12] that may be consistent with inter-
current viral infections. A similar scenario has been de-
scribed for HIV infection, in which chronic viral
infection alters the balance of naïve, central and effector
memory cells [46], and increases hyperactivation, immu-
nosenescence and apoptosis [34,47,48]. In our cohort,
CD4 T cells from CFS individuals and controls showed
similar levels of naïve (CD45RA+CCR7+CD27+CD28+),
central (CD45RA–CCR7+CD27+CD28+), transitional
(CD45RA–CCR7-CD27+CD28+), effector (CD45RA–CCR7-
CD27+CD28-) and terminally differentiated memory
(CD45RA-CCR7-CD27-CD28-) cells (Figure 3A and B).
Most CD8 T cell subsets were also similar in both groups,
although CFS affected individuals showed lower frequency
of cells with an effector phenotype (defined in CD8 T cells
by the following markers CD45RA-CCR7-CD27-CD28+,
Figure 3B). This observation maybe related with the lower
level of CD56 expression in CD3+ cells (Figure 1), al-
though the heterogeneity of this latter population impedes
a proper interpretation of these data. We also ana-
lyzed several markers of immunosenescence or immune
exhaustion, with discordant results: CFS and control indi-
viduals had similar expression of the T-cell immunosenes-
cence marker CD57 [46] in CD4 and CD8 T cells, while
differences were observed in the expression of exhaustion
markers PD-1 and CD95 [46] in CD4 and CD8 T cells,
respectively (Figure 3C).
We assessed the frequency of T regulatory cells (Treg)
and several proliferation/activation markers (Figure 4A).Treg cells defined as CD4+CD25++FOXP3+ or CD4+
CD25++FOXP3+CD127– showed significantly higher per-
centages in CFS individuals (Figure 4B and data not
shown), concomitant with lower levels of Ki67+ cells in
CD4 T cells (Figure 4B). In contrast, CD8 T cells did not
show differences among groups in Ki67 positivity, al-
though CFS individuals displayed higher expression of
CD5 (Figure 4B), a marker associated with impaired
T-cell responses [49,50]. CFS group also showed lower
levels of the activation marker CD38 in total and the
memory (CD45RO+) CD8 T cells (not shown and
Figure 4B). Despite these small differences in T-cell sub-
sets, ex vivo proliferative responses of CD4 T cells were
significantly lower in CFS individuals although showed
no differences among groups for CD8 T cells (Figure 4C).
Finally, no differences in cell death were noticed for
CD4 and CD8 T cells among groups (Figure 4D).
As a whole, these data suggest an impaired T-cell re-
sponse in CFS individuals associated with increased Treg
numbers and with some specific markers in both CD4
and CD8 T cells, but not directly caused by a general
status of immunosenescence.
Analysis of T-cell and NK-cell phenotype as markers for
CFS
In order to evaluate the potential utility of the described
immunological markers for the identification of CFS
cases, an unsupervised clustering analysis was perfor-
med. While unrestricted selection of markers provided
poor ability to separate CFS individuals and HD, mar-
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Figure 2 Analysis of NK cell phenotype in CFS affected individuals. Fresh blood was stained with the antibody combinations described in
Table 1. Panel A. NK cells were gated as CD3-CD19- PBMC and analyzed for CD16 and CD56 staining defining CD56 bright (R1), CD56+CD16+ (R2)
or CD16+ (R3) gates. Representative histograms showing the expression of NKp46 (upper plots) and CD57 (lower plots) are shown. Panel B. NK
cell subsets gated according to Panel A were analyzed for the expression of CD69 (upper), CD25 (middle) and NKp46 receptor is shown. Panel C.
In parallel, double positive CD56+CD16+ NK cells were analyzed for the expression of CD57, as the percentage of positive cells (upper graph) or
the Mean Fluorescence intensity (lower graph). In all cases, data from healthy donors (n = 25, HD) and SFC affected individuals (n = 19, SFC)
are shown, with median (thick lines), interquartile range (boxes) and 10–90 percentile values (bars). In all cases, p-values for nonparametric
Mann–Whitney comparison are shown.
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that showed the best resolution in classifying CFS and
healthy individuals (p = 3.3×10-8, Figure 5). The NK mar-
kers: CD25, CD69, NKp46 (expressed as percentage of
positive cells) and CD57 (as fluorescence intensity) in
combination with the T-cell subsets: regulatory, prolifer-
ating Ki67+CD4+, effector CD8+ and CD56+ T cells,
showed a high sensitivity (100%) but a moderate false
positive rate (5/24, specificity 79%, Figure 5). A more re-
strictive choice of parameters, including exclusively NK
cell markers showed similar false positive rates (5/23,specificity 78%) but lower sensitivity (95%) in the detec-
tion of CFS cases (Additional file 1: Figure S2).
Discussion
The immunological status of individuals suffering from
CFS has yielded heterogeneous results [12,17,31,51,52].
Clear examples are data from different CFS cohorts ana-
lyzed in a single laboratory [32]. These observations may
be the consequence of an intrinsic heterogeneity in the
classification of CFS affected individuals [3], or could be
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Figure 3 Analysis of CD4 and CD8 T cell subsets, immunosenescence and exhaustion. Panel A. Fresh blood was stained with the antibody
combinations described in Table 1. Different CD4 and CD8 T cell subpopulations (Naïve, Central memory, Transitional memory and Effector
memory) were identified by CD27, CD27 and then CCR7 and CD45RA expression as shown. Panel B. The median values for the frequency of the
indicated subsets in healthy donors and CFS affected individuals are shown in circular plots. Significant differences among groups are indicated.
Panel C. The entire CD4 and CD8 T cell gates were also analyzed for the expression of CD57, PD-1 and Fas-CD95. In all cases, data from healthy
donors (n = 25, HD) and SFC affected individuals (n = 19, SFC) are shown, with median (thick lines), interquartile range (boxes) and 10–90
percentile values (bars). In all cases, p-values for nonparametric Mann–Whitney comparison are shown.
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ticular, the prevalence of infections by herpesviruses or
enteroviruses [15], which have been described more fre-
quently in CFS individuals [18,53], are known to modu-
late immune phenotype [46]. We have performed a wide
screening of the phenotype and function of B, NK and T
cells in CFS. In contrast to other studies, our main in-
clusion criterion was focused on the lack of active in-
fections, rather than on the CFS-related comorbidities.
Although this could be a limitation, as comorbidities
may also affect immune status, we believed that these
criteria might provide a more homogeneous immune
profile of CFS.
Our data suggest that most differences between CFS
and healthy controls were observed in NK and T cells;
while the B-cell compartment showed similar com-
position in both groups. Importantly, these differences
could not be associated to polypharmacy or comorbidi-
ties (Additional file 1: Figure S3 and data not shown),
although the sample size of our study limited the sta-
tistical power of these analyses. The lack of B cellalterations observed in our study contrasts with the ac-
tive role of B cells and autoimmune responses in CFS
that have been highlighted by the recent clinical use of
Rituximab [19]. The possibility that B-cell alterations are
restricted to tissue B cells may explain this apparent
contradiction. However, it should be noted that in con-
trast to NK and T cell markers described herein, param-
eters of B cell phenotype showed heterogeneous values
and seem to be more affected by antioxidant/analgesic
treatments. This could be a second limitation of our
study; thus, a more detailed analysis of B cell phenotype
and function using larger cohorts will be required to
fully understand the role of these cells in CFS.
A different scenario is observed in NK cells. In this
case, several markers showed consistent alterations in
CFS individuals and illustrate a skewed NK cell popu-
lation with high CD69 and low CD25 expression, a pa-
radoxical phenotype that has been described in acute
influenza infection or vaccination [54] and that is in
clear conflict with recent data reporting low CD69 ex-









































































































































































































































































































Figure 4 Analysis of CD4 and CD8 T cell activation, proliferative capacity and death. Panel A. Gating strategy to analyze FOXP3 and Ki67
expression. CD4 and CD8 T cells were identified in a CD3+ gate. In CD4 T cells, the expression of FOXP3 and CD25 defined the Treg population,
while remaining cells were analyzed for Ki67 expression. In CD8 T cells, CD5 and Ki67 were analyzed in the whole population. Panel B. The entire
CD4 and CD8 T cell gates illustrated in Figure 3 were analyzed for the frequency of Treg (CD25+FOX–P3+) cells, or for the expression of the
indicated markers. In all cases, data from healthy donors (n = 25, HD) and SFC affected individuals (n = 19, SFC) are shown. Panel C. PBMC from
healthy donors (n = 5, HD) and CFS affected individuals (n = 8, CFS) were stained with CFSE and cultured in the presence of a combination of
PHA and IL-2 (PHA/IL-2). Data shown are proliferation index of gated CD4 or CD8 T cells calculated from best-fit curves using FlowJo software.
Panel D. PBMC from healthy donors (n = 30, HD) and CFS affected individuals (n = 19, CFS) were also cultured for 24 h to assess spontaneous CD4
or CD8 T-cell death using DIOC6 and PI staining. Results show total cell death defined by low DIOC6 fluorescence signal. In all panels, median
values (thick lines), interquartile ranges (boxes) and 10–90 percentile values (bars). In all cases, p-values for nonparametric Mann–Whitney
comparison are shown.
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http://www.translational-medicine.com/content/11/1/68[22,23]. Of note, this latter work measured CD69 expres-
sion done after in vitro stimulation while our data were
obtained using freshly obtained unstimulated cells. Thus,
although apparently in conflict, both data may reflect
different aspects of a deregulated CD69 expression in
CFS. We have also observed increased levels of NKp46
expression in CFS individuals. Interestingly the expres-
sion of this receptor has been recently linked to T-cell
responses in murine models [55]; however, no clear as-
sociation could be found in our cohort. The phenotype
of NK cells is controlled by genetic, epigenetic and en-
vironmental factors and probably summarizes the in-
fectious history of an individual in a poorly-understood
form of immunological memory [56]. Specific phenoty-
pes have been associated to infectious agents, such as
CMV or influenza [54,57]. Although it could be temp-
ting to speculate on a common infective history in ourcohort of CFS individuals, the analysis of their sero-
logical status for some viruses (CMV, EBV, parvoviruses)
did not show a clear link between past infections and
current NK-cell phenotype. Probably, wider studies are
required to answer this relevant question and to confirm
the association of NK-cell phenotype with impaired lytic
activity, which has been described in larger cohorts but
failed to reach significant differences in our limited
analysis, probably due to the small subset of samples an-
alyzed or to the use of EDTA as anticoagulant. NK func-
tion decreases with age, a phenomenon associated with
NK immunosenescence that can be evidenced by the in-
creased expression of CD57, present in terminally differ-
entiated NK cells [58]. However, there is no consensus
on the role of CD57 in immunosenescence of NK cells
and CFS has been associated with low expression of CD57
[59]; an observation partly confirmed in our cohort.
Figure 5 Clustering CFS individuals according to NK and T cell phenotypic markers. A subset of 19 CFS (red labels) and 25 control
individuals (green labels) was analyzed. Figure shows normalized centered data in yellow (for positive values, above median) and blue
(for negative values, below median). Two groups of CFS and Control individuals were clearly differentiated, while a heterogeneous subgroup was
clustered with CFS individuals.
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dividuals is related to T-cell phenotype and function,
which could be defined as a general hyporesponsiveness.
These data contrast with descriptions of high T-cell acti-
vation in CFS [12], but are consistent with other reports
describing reduced CD8 cytotoxic activity [9]. Again, the
presence of active viral infections at the sampling time
may be a source of heterogeneity. Alternatively, the leak-
age of bacterial products from gut may also determine
T-cell activation [60,61]. To explore this possibility, we
analyzed plasma levels of sCD14 In healthy and CFS indi-
viduals, showing similar median levels (4.5 and 4.7 μg/ml,
respectively, p = 0.44, data not shown), suggesting that gut
leakage is not a major contributor to immune alterations
in our cohort.
Our data may suggest a general default of T-cell func-
tion that can be observed using different makers in both
CD4 and CD8 subsets. While CD4 T cells show lower
Ki67 staining and ex vivo proliferation, CD8 T cells sho-
wed no proliferative differences, but lower levels of CD56
expression, effector (CCR7–CD45RA–) cells, CD38+ cells
and higher expression of CD5, a marker of anergy associ-
ated to continuous antigen exposure [50]. Furthermore,
this general status of T-cell hyporesponsiveness seems to
be unrelated to immunosenescence, since no differences
in CD57 or no increased levels of CD27- or CD28- cells
were observed between groups. A key factor in the control
of T cell responses is the function of Treg cells [62], which
are significantly increased in our cohort of CFS individuals
confirming data from another recent study [9]. Although
no clear correlation was observed between Treg frequency
and other markers of NK cell or T-cell phenotype; an ac-
tive role of Treg could be supported by reported data onkey mediators of Treg action, such as TGF-β [63], that
seem to be also upregulated in CFS individuals[64,65].
The potential use of the immunological markers iden-
tified in this study was explored in cluster analyses.
While the best resolution required both T and NK cell
markers, we also identified a robust combination of NK
cell markers that may be useful for diagnosis. This com-
bination includes CD25, CD69 and NKp46 expression in
CD56 + CD16+ cells and CD56 expression in CD3+ cells,
suggesting that a five-color flow cytometry strategy in-
cluding these markers may be useful for diagnostic pur-
poses. However, a wider range of parameters including
FOXP3 and Ki67 expression in CD4 T cells improved
specificity. The use of these potential combinations as
diagnostic tools requires validation in further studies, in-
cluding both larger cohorts and a wider range of CFS
clinical status.
In conclusion, CFS individuals analyzed in this study
show no differences in B-cell compartment, skewed NK
cells and poorly responsive T cells. The observed immu-
nological defaults do not provide any causative link to
the illness, but could explain some of the symptoms and
in particular the poor control of viral infections reported
in these individuals [15,53]. However, some of these
markers along with other previously described, such as
NK function or DPPIV [22,66] may be useful for the
characterization of CFS. However, major roadblocks still
exist to reach a reliable combination of immune bio-
markers for CFS. First, the potential different etiologies
or comorbidities of CFS and second the clear identifi-
cation of the target population (ME, CFS or both). In
addition, immunological markers may reveal only a part
or the complex pathogenic spectrum of ME/CFS. Most
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http://www.translational-medicine.com/content/11/1/68likely, immune features in combination with a detailed
analysis of intercurrent infections and previously des-
cribed [9,22,25,29,66,67]neurological and metabolic dis-
orders may provide the clues to define a full set of
markers helpful for our knowledge of CFS pathogen-
esis and for its clinical management.
Additional file
Additional file 1: Table S1. Main comorbidities identified in CFS
affected individuals. Figure S1. Analysis of B-cell subsets and
proliferation. Panel A. Gating strategy for the identification of B-cell
subsets. IgA, IgG and IgD expressing cells were identified in the CD19+
gate, the expression of CD27 in each subset was analyzed. Plasma cells
were identified by high CD38 and CD27 expression. Marginal Zone (MZ)
B cells by high CD1c expression and transitional cells by CD5, CD10 and
CD38 expression. Panel B. Fresh blood was stained with the antibody
combinations described in Table I, lysed washed and acquired. B-cell
subsets showed similar values in healthy donors (n = 27, HD, empty
boxes) and CFS individuals (n = 19, CFS, solid boxes). Panel C. PBMC were
stained with CFSE and cultured in the presence of the TLR9 agonist
CpG2006 and the TLR7/8 agonist R848. Values of division index
calculated using Flow Jo software from healthy donors (n = 5, HD, empty
boxes) and CFS individuals (n = 9, CFS, solid boxes) are shown. In all
cases, median values, interquartile ranges (boxes), 10-90 percentiles (bars)
and p-values for nonparametric Mann-Whitney comparison are shown.
Figure S2. Clustering CFS individuals according to NK cell phenotypic
markers. A subset of 19 CFS (red labels) and 25 control individuals (green
labels) was analyzed. Figure shows normalized centered data in yellow
(for positive values, above median) and blue (for negative values, below
median). NK cell parameters provided lower resolution than the
combination of NK and T cell dta. However, CFS and healthy donors
showed significant clustering (p = 3.1 × 10-7). Figure S3. Analysis of the
effect of antioxidant intake on main biomarkers of CFS. 25 control
individuals (HD) and 19 CFS individuals subgrouped according to
antioxidant treatment were analyzed. Figure shows median and
interquartile ranges for the 8 parameters defined in Figure 5. All figures
show p-values for 1-way ANOVA analyses of the three groups (upper left
corners) and p-values for Mann-Whitney comparisons between the CFS
subgroups (right).
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